<div id="readability-page-1"><p>Rovin Capital UT ADV acquired a new stake in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,355 shares of the company's stock, valued at approximately $207,000.</p><ul><li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li></ul><p>Other large investors have also bought and sold shares of the company. Brighton Jones LLC grew its position in  Johnson &amp; Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter.  Wealth Group Ltd. bought a new position in  Johnson &amp; Johnson during the first quarter worth about $218,000.  Smart Money Group LLC increased its position in  Johnson &amp; Johnson by 6.5% during the first quarter. Smart Money Group LLC now owns 6,687 shares of the company's stock worth $1,109,000 after buying an additional 407 shares during the last quarter.  John W. Brooker &amp; Co. CPAs lifted its position in shares of  Johnson &amp; Johnson by 9.8% in the first quarter. John W. Brooker &amp; Co. CPAs now owns 2,235 shares of the company's stock valued at $371,000 after buying an additional 200 shares during the last quarter.  Finally, Slagle Financial LLC lifted its holdings in  Johnson &amp; Johnson by 0.6% during the 1st quarter. Slagle Financial LLC now owns 14,114 shares of the company's stock valued at $2,341,000 after purchasing an additional 86 shares during the last quarter. 69.55% of the stock is owned by institutional investors. </p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><h2>Insider Activity</h2><p>In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Company insiders own  0.16% of the company's stock. </p><h2>Johnson &amp; Johnson Stock Performance</h2><ul><li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li></ul><p>Shares of NYSE:JNJ opened at $186.50 on Friday. Johnson &amp; Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The stock has a market capitalization of $449.34 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company's 50 day simple moving average is $184.25 and its 200 day simple moving average is $168.63. </p><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter.  As a group, research analysts predict that  Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year. </p><h2>Johnson &amp; Johnson Announces Dividend</h2><ul><li>Johnson &amp; Johnson Stock Can Keep Rising as Strategy Pays Off</li></ul><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson &amp; Johnson's dividend payout ratio (DPR) is presently 50.19%. </p><h2>Wall Street Analyst Weigh In</h2><p>Several equities analysts have recently weighed in on the stock. Daiwa America raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday, October 20th. Cowen  reissued a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a report on Tuesday, October 14th. JPMorgan Chase &amp; Co. upped their target price on Johnson &amp; Johnson from $185.00 to $200.00 and gave the company a &#34;neutral&#34; rating in a research report on Tuesday, September 16th. Wall Street Zen upgraded Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, September 13th. Finally, Guggenheim raised Johnson &amp; Johnson from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned  a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $199.05.</p><p><b>Get Our Latest Stock Analysis on Johnson &amp; Johnson</b></p><h2>About Johnson &amp; Johnson</h2> (Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>See Also</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>3 Defense Stocks Set to Benefit From Increased Military Spending</li><li>OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever</li><li>Asset Allocation Strategies in Volatile Markets</li><li>2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail</li><li>The How And Why of Investing in Oil Stocks</li><li>CrowdStrike Partners With CoreWeave But Investors Sell the News</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Rovin Capital UT ADV acquired 1,355 shares of Johnson & Johnson (NYSE: JNJ) valued at approximately $207,000 during the 2nd quarter. Other investors, including Brighton Jones LLC and Smart Money Group LLC, also increased their stakes in the company. Johnson & Johnson's stock opened at $186.50, with a market cap of $449.34 billion. The company recently declared a quarterly dividend of $1.30, with a yield of 2.8%. Analysts have upgraded their ratings on the stock, with target prices reaching up to $200.00.</p>

1,355 Shares in Johnson & Johnson $JNJ Bought by Rovin Capital UT ADV